What is Immunome's revenue?

Immunome (IMNM) generated $4.0M in revenue over the trailing twelve months, down 63.3% year over year.

Is Immunome profitable?

Immunome is not currently profitable: it reported a net loss of $224.6M over the trailing twelve months, a -5593.8% net margin.

What is Immunome's earnings per share?

Immunome's diluted EPS over the trailing twelve months is $-2.38.

Where does Immunome's income statement data come from?

Every line is extracted from Immunome's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Immunome IMNM Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Net interest income	$11.72M-8.7%	$12.84M+371%	$2.72M+54,380%	$5K+150%
Total revenue	$6.94M-23.2%	$9.04M-35.5%	$14.02M—	——
Research and development	$177.29M+36.9%	$129.54M+461%	$23.09M-0.8%	$23.27M+64.9%
General and administrative	$43.77M+32.8%	$32.96M+67.7%	$19.66M+44.2%	$13.63M+22.9%
Total operating expenses	$231.05M-26.6%	$314.84M+155%	$123.55M+235%	$36.9M+46.4%
Operating income	-$224.11M+26.7%	-$305.8M-179%	-$109.53M-197%	-$36.9M-46.4%
Operating margin	-3,228.8%+154pp	-3,382.4%-2,601pp	-781.4%—	——
Net income	-$212.39M+27.5%	-$292.96M-174%	-$106.81M-189%	-$36.9M-49.3%
Net margin	-3,060%+180pp	-3,240.4%-2,478pp	-761.9%—	——
Diluted earnings per share	-$2.42+53.2%	-$5.17+4.1%	-$5.39-74.4%	-$3.09-45.1%
Basic earnings per share	-$2.42+53.2%	-$5.17+4.1%	-$5.39-74.4%	-$3.09-45.1%
Weighted-average shares, diluted	341.7M+48.4%	230.3M+308%	56.4M+16.3%	48.5M+6.4%
Weighted-average shares, basic	341.7M+48.4%	230.3M+308%	56.4M+16.3%	48.5M+6.4%
Debt securities, available-for-sale, unrealized gain	——	——	$22K—	——
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	-$212.45M+27.5%	-$292.93M-174%	-$106.78M-185%	-$37.52M—
Gain (loss) on available-for-sale debt securities	——	——	——	——
Interest Income (Expense), Operating	$11.72M-8.7%	$12.84M+371%	$2.72M+54,380%	$5K+150%
Revenue From Contract With Customer Excluding Assessed Tax	$6.94M-23.2%	$9.04M-35.5%	$14.02M—	——
EBIT	-$224.11M+26.7%	-$305.8M-179%	-$109.53M-197%	-$36.9M-46.4%
EBITDA	-$221.65M+27.1%	-$304.23M-179%	-$109.07M-199%	-$36.48M-49.2%
EBITDA	-$221.65M+27.1%	-$304.23M-179%	-$109.07M-199%	-$36.48M-49.2%
EBITDA margin	-3,193.3%+172pp	-3,365%-2,587pp	-778.1%—	——
EBIT	-$224.11M+26.7%	-$305.8M-179%	-$109.53M-197%	-$36.9M-46.4%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Immunome.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Immunome's revenue?: Immunome (IMNM) generated $4.0M in revenue over the trailing twelve months, down 63.3% year over year.
Is Immunome profitable?: Immunome is not currently profitable: it reported a net loss of $224.6M over the trailing twelve months, a -5593.8% net margin.
What is Immunome's earnings per share?: Immunome's diluted EPS over the trailing twelve months is $-2.38.
Where does Immunome's income statement data come from?: Every line is extracted from Immunome's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.